Literature DB >> 17846969

Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study.

C Koehler1, P Ott, I Benke, M Hanefeld.   

Abstract

UNLABELLED: This study investigated the prevalence of the metabolic syndrome (MetS) in a German population with type 2 diabetes (T2DM) using the three definitions for MetS according to WHO 1999, AHA/NHLBI 2005, and IDF 2005 criteria. Four-thousand and twenty participants as a cross section of daily practice of diabetes care in Germany (238 unselected sites) were included in the Diabetes in Germany (DIG) study. INCLUSION CRITERIA: T2DM and age between 35-80 years. EXCLUSION CRITERIA: major cardiovascular event < 3 months before entry, NYHA-IV, macroproteinuria, and cancer < 5 years before entry. The components of MetS were measured following a standard protocol for anthropometric and laboratory control. The average diabetes duration was 8.4 years and HbA (1C) 7.0%. The prevalence of MetS by WHO criteria was 26.1%, by AHA/NHLBI 79.3%, and by IDF 82.6%. The degree of agreement (kappa statistic) was kappa = 0.69 between AHA/NHLBI and IDF definitions, but only 0.12 for WHO VS. IDF, and 0.17 for WHO vs. AHA/NHLBI. The frequency of central obesity by WHO was 50.9%, by AHA/NHLBI 72.9%, and by IDF 92.0% and for hypertension 29.3%, 92.6%, and 92.6%, respectively. However, the frequencies of lipid components by the three definitions were in the same range (57.8%, 59.5%, 59.5%). In this representative German sample of patients with type 2 diabetes, the prevalence of MetS was very highly independent of using the IDF or AHA/NHLBI definition. Females were significantly more affected than males. The distinctly lower prevalence delineated from WHO criteria is due to low frequency of central obesity and hypertension as consequence of higher cutoff limits for these components used in the WHO definition.

Entities:  

Mesh:

Year:  2007        PMID: 17846969     DOI: 10.1055/s-2007-985816

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  17 in total

1.  The JCR:LA-cp rat: a novel rodent model of cystic medial necrosis.

Authors:  Yuh Fen Pung; William M Chilian; Martin R Bennett; Nichola Figg; Mohd Hamzah Kamarulzaman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-12-16       Impact factor: 4.733

2.  Association between Elder Abuse and Metabolic Syndromes: Findings from the Chicago Health and Aging Project.

Authors:  XinQi Dong; Melissa Simon
Journal:  Gerontology       Date:  2014-11-29       Impact factor: 5.140

3.  Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study.

Authors:  Ala'a Alkerwi; Anne-Françoise Donneau; Nicolas Sauvageot; Marie-Lise Lair; André Scheen; Adelin Albert; Michèle Guillaume
Journal:  BMC Public Health       Date:  2011-01-04       Impact factor: 3.295

4.  Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management.

Authors:  Ah Young Kang; Su Kyung Park; So Young Park; Hye Jeong Lee; Ying Han; Sa Ra Lee; Sung Hwan Suh; Duk Kyu Kim; Mi Kyoung Park
Journal:  Diabetes Metab J       Date:  2011-06-30       Impact factor: 5.376

5.  A comparison of predictability of cardiovascular events between each metabolic component in patients with metabolic syndrome based on the revised National Cholesterol Education Program criteria.

Authors:  In-Cheol Hwang; Kyoung-Kon Kim; Sun-Ha Jee; Hee-Cheol Kang
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

6.  Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.

Authors:  Roland E Schmieder; Anselm K Gitt; Cornelia Koch; Peter Bramlage; Taoufik Ouarrak; Diethelm Tschöpe
Journal:  BMC Endocr Disord       Date:  2015-05-02       Impact factor: 2.763

7.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

8.  Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes.

Authors:  Ki-Bum Won; Hyuk-Jae Chang; Hyeon-Chang Kim; Kyewon Jeon; Hancheol Lee; Sanghoon Shin; In-Jeong Cho; Sung-Ha Park; Sang-Hak Lee; Yangsoo Jang
Journal:  Cardiovasc Diabetol       Date:  2013-03-04       Impact factor: 9.951

9.  Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE.

Authors:  Anselm K Gitt; Roland E Schmieder; Eva Duetting; Peter Bramlage; Steffen Schneider; Diethelm Tschöpe
Journal:  Cardiovasc Diabetol       Date:  2012-12-05       Impact factor: 9.951

10.  Metabolic syndrome and diabetes, alone and in combination, as predictors of cardiovascular disease mortality among men.

Authors:  Timothy S Church; Angela M Thompson; Peter T Katzmarzyk; Xuemei Sui; Neil Johannsen; Conrad P Earnest; Steven N Blair
Journal:  Diabetes Care       Date:  2009-04-14       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.